3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lymphoma, Follicular
5
Breast Neoplasms
5
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Pancreatic Neoplasms
3
Neoplasms
3
Melanoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma, Mantle-Cell
2
Leukemia
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Burkitt Lymphoma
2
Brain Neoplasms
2
Virus Diseases
1
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled